The Stomach Exam Japan Gives Millions — and America Mostly Skips

In Japan, turning 50 comes with a quiet, unglamorous ritual: an invitation to be screened for stomach cancer. Depending on the municipality, that means either a barium X-ray of the upper digestive tract or a direct look inside with an endoscope, repeated every two years for as long as it’s needed. In the United States, that invitation simply doesn’t exist. There is no standard test, no age-based recall letter, and no major medical body recommending one for the average adult.

This isn’t a story about a breakthrough drug or a rare procedure. It’s a story about a basic screening habit — one country runs it as public health infrastructure, the other doesn’t run it at all.

How Japan’s program works

Japan has been screening for stomach (gastric) cancer since the 1960s, when nationwide radiographic (barium X-ray) screening began. In 2014, revised national guidelines formally approved endoscopy — a thin camera passed down the esophagus into the stomach — as an equally valid population-screening method alongside X-ray. Today, Japanese guidance recommends screening every two years starting at age 50 (the program originally started at 40 and ran annually, before the interval and starting age were adjusted as incidence patterns shifted). During the exam, a gastroenterologist can spot early lesions and, in many cases, remove suspicious tissue or take a biopsy in the same session.

The scale is real: this is a nationally organized program, similar in spirit to how the U.S. organizes mammography or colonoscopy screening, but built around a cancer that barely registers on the American radar.

Why Japan built this

The reason is epidemiological. Stomach cancer is still one of the most common cancers diagnosed in Japan — by recent figures it ranks among the top two or three cancers by incidence, accounting for roughly a tenth of the country’s annual cancer deaths. Over 99% of gastric cancers in Japan are linked to chronic Helicobacter pylori infection, a bacterium historically far more prevalent there than in the West. That combination — high incidence, a well-understood cause, and a screening tool that can catch cancer at a curable, early stage — is exactly the profile that makes population-wide screening worthwhile.

Where the United States stands

Stomach cancer is a far less common diagnosis in the U.S., which is precisely why no major American organization — not the American Cancer Society, not the National Cancer Institute — recommends routine screening for it in average-risk adults. The official guidance is direct: there is no standard or routine screening test for stomach cancer in the general U.S. population, because for most people the risks and costs of screening (unnecessary procedures, false alarms) are judged not to outweigh the benefit for a relatively rare disease. Endoscopic surveillance is sometimes offered in the U.S., but only to people already flagged as higher-risk — those with precancerous stomach conditions, certain polyps, pernicious anemia, or a strong family history. Absent those flags, most American stomach cancers are found only after symptoms appear, which is one reason they tend to be caught at a later, harder-to-treat stage.

Why this gap exists

This isn’t a case of one country’s medicine being better than the other’s. Population screening only makes sense where a disease is common enough, and its natural history predictable enough, that catching it early changes outcomes at scale. Japan’s disease burden justified building that infrastructure decades ago; the U.S., with a much lower baseline incidence, made a different — and by its own numbers, reasonable — calculation. But the practical result is a real gap in what’s routinely offered to two similar 50-year-olds depending on which country they live in.

The bigger pattern: comprehensive screening

This is really a small piece of a larger philosophy. Japan’s Ningen Dock comprehensive health exam — the model our own screenings are built around — often includes an upper endoscopy as a standard component, precisely because of programs like this one. It’s a useful reminder of what “preventive care” can look like when it’s built as a system rather than assembled one risk factor at a time.

We’ll keep tracking these gaps — the drugs, procedures, and screening habits where Japan is ahead — here in The Mirai Journal each week.

Sources: Gastric Cancer Screening in Japan: A Narrative Review, PMC; Effect and cost-effectiveness of national gastric cancer screening in Japan, PMC; American Cancer Society — Stomach Cancer Early Detection, Diagnosis, and Staging; National Cancer Institute — Screening for Stomach Cancer.